This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by De Crée, J. Articles by Verhaegen, H. Search for Related Content PubMed PubMed Citation Articles by De Crée, J. Articles by Verhaegen, H. Social Bookmarking                         What's this?

Comparison of the Subacute Hemodynamic Effects of Atenolol, Propranolol, Pindolol, and Nebivolol

Clinical Research Unit St. Bartholomeus, Jan Palfijn Hospital, Merksem, Belgium

Carlos Cobo

Clinical Research Unit St. Bartholomeus, Jan Palfijn Hospital, Merksem, Belgium

Hedwig Geukens

Clinical Research Unit St. Bartholomeus, Jan Palfijn Hospital, Merksem, Belgium

Herman Verhaegen

Clinical Research Unit St. Bartholomeus, Jan Palfijn Hospital, Merksem, Belgium

In an observer-blind four-way crossover study, 7 healthy volunteers received in random sequence, one month apart, atenolol 100 mg od, propranolol (slow release) 160 mg od, pindolol 5 mg tid, and nebivolol 5 mg od for a period of seven days, followed by a single-blind placebo washout period of seven days. The decrease of peak exercise heart rate and systolic blood pressure was significant (p = 0.02) and comparable for the four drugs studied and varied between 15% and 23% for heart rate and between 15% and 20% for systolic blood pressure. Although no statistically significant difference was observed among the four drug regimens, the decrease of peak exercise heart rate was less pronounced with nebivolol than with the three reference beta-blocking agents. The ratio of the preejection period (PEP_c) to the left ventricular ejection time (LVET _c), an indirect measure of left ventricular performance, tended to increase with atenolol and propranolol and remained unchanged with pindolol. PEP _c/LVET_c progressively and significantly improved with nebivolol from a control value of 0.37 ± 0.012 to 0.31 ± 0.009 (p = 0.03) after seven days of treatment, owing to a decrease in PEP_c and an increase in LVET_c, suggestive of a combined effect both on preload and afterload. Postexercise LVET_c, an index of the intrinsic positive inotropy of exercise, was significantly suppressed by atenolol, propranolol, and pindolol, but not during treating with nebivolol.

These data suggest that nebivolol is a ß1-selective adrenergic antagonist with an unusual hemodynamic profile, probably improving left ventricular compliance.

Angiology, Vol. 41, No. 2, 95-105 (1990)
DOI: 10.1177/000331979004100202


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. M. Prisant Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory {beta}1-Blocker J. Clin. Pharmacol., February 1, 2008; 48(2): 225 - 239. [Abstract] [Full Text] [PDF]